PubRank

Thomas F Gajewski

Author PubWeight™ 118.66‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med 2013 5.82
2 PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res 2004 5.59
3 Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med 2011 4.02
4 Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res 2009 3.83
5 Cancer classification using the Immunoscore: a worldwide task force. J Transl Med 2012 2.88
6 The immune score as a new possible approach for the classification of cancer. J Transl Med 2012 2.79
7 PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood 2009 2.54
8 Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol 2009 2.53
9 Glucose availability regulates IFN-gamma production and p70S6 kinase activation in CD8+ effector T cells. J Immunol 2005 2.51
10 T cell anergy is reversed by active Ras and is regulated by diacylglycerol kinase-alpha. Nat Immunol 2006 2.42
11 Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother 2004 2.42
12 Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer 2006 2.40
13 Defining the critical hurdles in cancer immunotherapy. J Transl Med 2011 2.32
14 Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity 2002 2.18
15 Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol 2013 2.11
16 B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism. J Exp Med 2003 1.92
17 Glucose deprivation inhibits multiple key gene expression events and effector functions in CD8+ T cells. Eur J Immunol 2008 1.89
18 Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma. Clin Cancer Res 2008 1.85
19 Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J Clin Oncol 2003 1.72
20 Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients. Clin Cancer Res 2012 1.63
21 Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases. J Immunol 2007 1.60
22 Type I interferon response and innate immune sensing of cancer. Trends Immunol 2012 1.59
23 Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites. Cancer Immunol Immunother 2006 1.57
24 Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J Clin Oncol 2002 1.56
25 Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time. J Magn Reson Imaging 2004 1.54
26 Innate immune recognition of cancer. Annu Rev Immunol 2015 1.52
27 Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection. J Immunol 2006 1.51
28 Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol Rev 2009 1.44
29 On the TRAIL toward death receptor-based cancer therapeutics. J Clin Oncol 2007 1.27
30 Absence of programmed death receptor 1 alters thymic development and enhances generation of CD4/CD8 double-negative TCR-transgenic T cells. J Immunol 2003 1.26
31 Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer. Curr Opin Investig Drugs 2010 1.22
32 Induction of cytotoxic granules in human memory CD8+ T cell subsets requires cell cycle progression. J Immunol 2006 1.20
33 Actin cytoskeleton regulates calcium dynamics and NFAT nuclear duration. Mol Cell Biol 2004 1.18
34 Molecular regulation of T-cell anergy. EMBO Rep 2008 1.16
35 Transcriptional regulator early growth response gene 2 (Egr2) is required for T cell anergy in vitro and in vivo. J Exp Med 2012 1.16
36 Beta-catenin does not regulate memory T cell phenotype. Nat Med 2010 1.13
37 Negative regulation of T-cell function by PD-1. Crit Rev Immunol 2004 1.11
38 Production of TH1 and TH2 cell lines and clones. Curr Protoc Immunol 2006 1.10
39 Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma. Invest New Drugs 2012 1.09
40 Cutting edge: cytotoxic granule polarization and cytolysis can occur without central supramolecular activation cluster formation in CD8+ effector T cells. J Immunol 2005 1.08
41 CD40 ligation reverses T cell tolerance in acute myeloid leukemia. J Clin Invest 2013 1.04
42 Formation of a central supramolecular activation cluster is not required for activation of naive CD8+ T cells. Proc Natl Acad Sci U S A 2004 1.03
43 SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools - a compass in the land of biomarker discovery. J Transl Med 2011 1.02
44 Use of Cre-adenovirus and CAR transgenic mice for efficient deletion of genes in post-thymic T cells. J Immunol Methods 2007 1.02
45 Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma. Cancer Immunol Immunother 2008 1.01
46 Beta-catenin inhibits T cell activation by selective interference with linker for activation of T cells-phospholipase C-γ1 phosphorylation. J Immunol 2010 0.99
47 Gene array and protein expression profiles suggest post-transcriptional regulation during CD8+ T cell differentiation. J Biol Chem 2003 0.98
48 Cellular and molecular requirements for rejection of B16 melanoma in the setting of regulatory T cell depletion and homeostatic proliferation. J Immunol 2012 0.97
49 Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012". J Transl Med 2013 0.95
50 Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies. J Clin Oncol 2004 0.94
51 ICAM-1 contributes to but is not essential for tumor antigen cross-priming and CD8+ T cell-mediated tumor rejection in vivo. J Immunol 2005 0.92
52 Death of peripheral CD8+ T cells in the absence of MHC class I is Fas-dependent and not blocked by Bcl-xL. Eur J Immunol 2003 0.92
53 A designer ligand specific for Kv1.3 channels from a scorpion neurotoxin-based library. Proc Natl Acad Sci U S A 2009 0.91
54 Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma. Clin Cancer Res 2004 0.90
55 Differential Ras signaling via the antigen receptor and IL-2 receptor in primary T lymphocytes. Biochem Biophys Res Commun 2003 0.90
56 An adenoviral vector encoding dominant negative Cbl lowers the threshold for T cell activation in post-thymic T cells. Cell Immunol 2007 0.89
57 The composition of the microbiota modulates allograft rejection. J Clin Invest 2016 0.88
58 Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011". J Transl Med 2012 0.87
59 Cancer immunotherapy. Curr Opin Immunol 2013 0.87
60 Farnesyltransferase inhibitors inhibit T-cell cytokine production at the posttranscriptional level. Blood 2007 0.86
61 Evidence implicating the Ras pathway in multiple CD28 costimulatory functions in CD4+ T cells. PLoS One 2011 0.85
62 Disparate functions of immature and mature human myeloid dendritic cells: implications for dendritic cell-based vaccines. J Leukoc Biol 2003 0.85
63 A phase II study of oxaliplatin, docetaxel, and GM-CSF in patients with previously treated advanced melanoma. Cancer Chemother Pharmacol 2009 0.85
64 Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901. J Immunother 2005 0.84
65 Improved melanoma survival at last! Ipilimumab and a paradigm shift for immunotherapy. Pigment Cell Melanoma Res 2010 0.83
66 Diagnosis and treatment of mycoplasma-contaminated cell cultures. Curr Protoc Cytom 2008 0.83
67 The host STING pathway at the interface of cancer and immunity. J Clin Invest 2016 0.83
68 Lymphatic vessels regulate immune microenvironments in human and murine melanoma. J Clin Invest 2016 0.82
69 Egr2-dependent gene expression profiling and ChIP-Seq reveal novel biologic targets in T cell anergy. Mol Immunol 2013 0.82
70 Cutting edge: targeted ligation of CTLA-4 in vivo by membrane-bound anti-CTLA-4 antibody prevents rejection of allogeneic cells. J Immunol 2002 0.82
71 T cell development and function in CrkL-deficient mice. Eur J Immunol 2003 0.82
72 A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma. Invest New Drugs 2006 0.81
73 A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer. Lung Cancer 2003 0.80
74 Workshop on immunotherapy combinations. Society for Immunotherapy of Cancer annual meeting Bethesda, November 3, 2011. J Transl Med 2012 0.80
75 Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013. J Transl Med 2014 0.80
76 Conditional deletion of PTEN in peripheral T cells augments TCR-mediated activation but does not abrogate CD28 dependency or prevent anergy induction. J Immunol 2013 0.79
77 Metabolic mechanisms of tumor resistance to T cell effector function. Immunol Res 2005 0.78
78 Cross-priming of T cells to intracranial tumor antigens elicits an immune response that fails in the effector phase but can be augmented with local immunotherapy. J Neuroimmunol 2006 0.78
79 Temozolomide for melanoma: new toxicities and new opportunities. J Clin Oncol 2004 0.78
80 Homeostatic proliferation of naïve CD8+ T cells depends on CD62L/L-selectin-mediated homing to peripheral LN. Eur J Immunol 2009 0.78
81 Flt-3 ligand and sequential FL/interleukin-2 in patients with metastatic renal carcinoma: clinical and biologic activity. J Immunother 2002 0.78
82 Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma. Cancer Imaging 2014 0.78
83 Protein kinase Ctheta focusing at the cSMAC is a consequence rather than cause of TCR signaling and is dependent on the MEK/ERK pathway. J Immunol 2009 0.77
84 The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer. Prostate 2009 0.76
85 Review of the 25th annual scientific meeting of the International Society for Biological Therapy of Cancer. J Transl Med 2011 0.75
86 Lymphoma-infiltrating immune cells. N Engl J Med 2005 0.75
87 Germ Warfare. Sci Am 2016 0.75
88 Diagnosis and treatment of Mycoplasma-contaminated cell cultures. Curr Protoc Microbiol 2006 0.75
89 Ocular melanoma metastasis to the cervical spine. J Clin Neurosci 2012 0.75
90 Innovations and challenges in melanoma: summary statement from the first Cambridge conference. Clin Cancer Res 2006 0.75
91 Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics. J Immunother 2007 0.75
92 Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-α2b in patients with metastatic melanoma. Melanoma Res 2017 0.75
93 Melanoma presenting as circulating tumor cells associated with failed angiogenesis. Melanoma Res 2008 0.75